{"active":true,"archived":false,"category":"Coronavirus","closed":true,"closedTime":"2022-07-27T14:41:40.366Z","commentCount":0,"competitive":0,"createdAt":"2022-07-27T14:41:40.366Z","creationDate":"2021-12-14T00:00:00Z","cumulativeMarkets":false,"cyom":false,"deploying":false,"description":"This market will resolve to “Yes” if, by December 31, 2021, 11:59:59 PM ET, Molnupiravir (also known under MK-4482, EIDD-2801 or Lagervio), or any product containing it receives an Emergency Use Authorization (EUA) or full approval from the FDA for treating COVID-19. \n\nOtherwise, this market will resolve to “No.” \n\nIf the resolution source isn’t updated by the resolution date, credible news reports may be used instead.\n\n----------------------------\n\nMolnupilavir, sold under the brand name Lagevrio among others, is an antiviral medication that inhibits the replication of certain RNA viruses, is used to treat COVID-19 in those infected by SARS-CoV-2 and is already approved by official health agencies in various countries (ie. UK, Bangladesh).\n\nLearn more about it: https://en.wikipedia.org/wiki/Molnupiravir\nhttps://www.ema.europa.eu/en/news/covid-19-ema-starts-rolling-review-molnupiravir\nhttps://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra","enableNegRisk":false,"endDate":"2021-12-31T00:00:00Z","featured":false,"icon":"","id":"5433","image":"","liquidity":0,"liquidityAmm":0,"liquidityClob":0,"markets":[{"active":true,"approved":true,"archived":false,"bestAsk":1,"bestBid":0,"category":"Coronavirus","clearBookOnStart":true,"clobTokenIds":"[\"44692797048474105811399815063775339778611688234352538645663297536215467075290\", \"76898789486469479638534975993193979048886446617620539907399761661951271572205\"]","closed":true,"closedTime":"2021-12-25 01:08:05+00","competitive":0,"conditionId":"0xcb68a05a16ef6ee1ad287d39cbd541d94e2de4e46aba7f2c4f5bede18beb2ab6","createdAt":"2021-12-14T23:28:51.165Z","creator":"","cyom":false,"deploying":false,"description":"This market will resolve to “Yes” if, by December 31, 2021, 11:59:59 PM ET, Molnupiravir (also known under MK-4482, EIDD-2801 or Lagervio), or any product containing it receives an Emergency Use Authorization (EUA) or full approval from the FDA for treating COVID-19. \n\nOtherwise, this market will resolve to “No.” \n\nIf the resolution source isn’t updated by the resolution date, credible news reports may be used instead.\n\n----------------------------\n\nMolnupilavir, sold under the brand name Lagevrio among others, is an antiviral medication that inhibits the replication of certain RNA viruses, is used to treat COVID-19 in those infected by SARS-CoV-2 and is already approved by official health agencies in various countries (ie. UK, Bangladesh).\n\nLearn more about it: https://en.wikipedia.org/wiki/Molnupiravir\nhttps://www.ema.europa.eu/en/news/covid-19-ema-starts-rolling-review-molnupiravir\nhttps://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhra","endDate":"2021-12-31T00:00:00Z","endDateIso":"2021-12-31","featured":false,"fee":"20000000000000000","feesEnabled":false,"fpmmLive":true,"funded":false,"hasReviewedDates":true,"holdingRewardsEnabled":false,"icon":"","id":"240038","image":"","lastTradePrice":0,"liquidity":"100.351819","liquidityNum":100.35,"mailchimpTag":"3925851","manualActivation":false,"marketMakerAddress":"0xc578452835a2880E6Ca1BE57Ec64D76086A40C79","marketType":"normal","negRiskOther":false,"new":false,"oneDayPriceChange":0,"oneHourPriceChange":0,"oneMonthPriceChange":0,"oneWeekPriceChange":0,"oneYearPriceChange":0,"outcomePrices":"[\"0.9999992443672236808022307655119916\", \"0.000000755632776319197769234488008364242\"]","outcomes":"[\"Yes\", \"No\"]","pagerDutyNotificationEnabled":false,"pendingDeployment":false,"question":"Will the FDA give emergency use authorization or otherwise approve Molnupiravir before 2022?","ready":false,"readyForCron":true,"requiresTranslation":false,"resolutionSource":"https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs","resolvedBy":"0x0dD333859cF16942dd333D7570D839b8946Ac221","restricted":false,"rewardsMaxSpread":0,"rewardsMinSize":0,"rfqEnabled":false,"sentDiscord":false,"slug":"will-the-fda-give-emergency-use-authorization-or-otherwise-approve-molnupiravir-before-2022","spread":1,"startDate":"2021-12-16T22:55:46.875Z","startDateIso":"2021-12-16","submitted_by":"0x790A4485e5198763C0a34272698ed0cd9506949B","twitterCardLastRefreshed":"1640394076337","twitterCardLocation":"https://polymarket-upload.s3.us-east-2.amazonaws.com/will-the-fda-give-emergency-use-authorization-or-otherwise-approve-molnupiravir-before-2022.png?1640394076336","umaResolutionStatuses":"[]","updatedAt":"2023-01-31T19:58:10.563Z","updatedBy":15,"volume":"16228.587722","volume1mo":0,"volume1moAmm":0,"volume1moClob":0,"volume1wk":0,"volume1wkAmm":0,"volume1wkClob":0,"volume1yr":0,"volume1yrAmm":0,"volume1yrClob":0,"volume24hr":0,"volumeNum":16228.59,"wideFormat":false}],"negRiskAugmented":false,"new":false,"openInterest":0,"pendingDeployment":false,"published_at":"2022-07-27 14:41:40.363+00","requiresTranslation":false,"resolutionSource":"https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization#coviddrugs","restricted":false,"showAllOutcomes":false,"showMarketImages":true,"slug":"will-the-fda-give-emergency-use-authorization-or-otherwise-approve-molnupiravir-before-2022","sortBy":"ascending","startDate":"2021-12-16T00:00:00Z","tags":[{"forceShow":false,"id":"100215","label":"All","requiresTranslation":false,"slug":"all","updatedAt":"2025-12-18T03:27:54.040735Z"}],"ticker":"will-the-fda-give-emergency-use-authorization-or-otherwise-approve-molnupiravir-before-2022","title":"Will the FDA give emergency use authorization or otherwise approve Molnupiravir before 2022?","updatedAt":"2024-03-22T01:51:37.572214Z","volume":16228.59,"volume1mo":0,"volume1wk":0,"volume1yr":0,"volume24hr":0}